Risk factors for resistant gram-positive bacteremia in febrile neutropenic patients with cancer

被引:0
作者
Lee, Minkyeong [1 ,2 ,4 ,5 ]
Lee, Chan Mi [1 ,2 ]
Byun, Ja min [1 ,2 ,3 ]
Shin, Dong-Yeop [1 ,2 ,3 ]
Koh, Youngil [1 ,2 ,3 ]
Hong, Junshik [1 ,2 ,3 ]
Choe, Pyoeng Gyun [1 ,2 ]
Park, Wan Beom [1 ,2 ]
Kim, Nam Joong [1 ,2 ]
Yoon, Sung-Soo [1 ,2 ,3 ]
Oh, Myoung-don [1 ,2 ]
Kang, Chang Kyung [1 ,2 ]
Kim, Inho [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ Hosp, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea
[2] Seoul Natl Univ, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] Chungbuk Natl Univ Hosp, Dept Internal Med, Div Infect Dis, Cheongju, South Korea
[5] Chungbuk Natl Univ, Coll Med, Cheongju, South Korea
关键词
Febrile neutropenia; Bacteremia; Gram-positive bacteria; Resistance; Cancer; INFECTIOUS-DISEASES SOCIETY; GUIDELINES; MANAGEMENT; MORTALITY; THERAPY; UPDATE; ERA;
D O I
10.1016/j.jiac.2024.03.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Gram-positive bacteria are frequently resistant to empirical beta-lactams in febrile neutropenic patients with cancer. As microbiology and antibiotic susceptibility changes, we reevaluated the risk factors for resistant Gram-positive bacteremia in febrile neutropenic patients with cancer. Methods: Episodes of bacteremic febrile neutropenia in Seoul National University Hospital from July 2019 to June 2022 were reviewed. Resistant Gram-positive bacteria were defined as a pathogen susceptible only to glycopeptide or linezolid in vitro (e.g., methicillin-resistant staphylococci, penicillin-resistant viridans streptococci, and ampicillin-resistant enterococci). Episodes were compared to identify independent risk factors for resistant Gram-positive bacteremia. Results: Of 225 episodes, 78 (34.7%) involved resistant Gram-positive bacteremia. Multivariate analysis revealed that breakthrough bacteremia while being administered antibiotics (adjusted odds ratio [aOR], 6.794; 95% confidence interval [95% CI], 3.130-14.749; P < 0.001) and catheter-related infection (aOR 4.039, 95% CI 1.366-11.946; P = 0.012) were associated with resistant Gram-positive bacteremia. Chronic liver disease (aOR 0.231, 95% CI 0.059-0.905; P = 0.035) and hypotension at bacteremia (aOR 0.454, 95% CI 0.218-0.945; P = 0.035) were inversely associated with resistant Gram-positive bacteremia. Conclusions: Resistant Gram-positive bacteria should be considered in breakthrough bacteremia and catheterrelated infection in febrile neutropenic patients with cancer.
引用
收藏
页码:995 / 1000
页数:6
相关论文
共 23 条
  • [1] Management of febrile neutropenia in the era of bacterial resistance
    Alp, Sehnaz
    Akova, Murat
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2013, 1 (01) : 37 - 43
  • [2] European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia
    Averbuch, Diana
    Orasch, Christina
    Cordonnier, Catherine
    Livermore, David M.
    Mikulska, Malgorzata
    Viscoli, Claudio
    Gyssens, Inge C.
    Kern, Winfried V.
    Klyasova, Galina
    Marchetti, Oscar
    Engelhard, Dan
    Akova, Murat
    [J]. HAEMATOLOGICA, 2013, 98 (12) : 1826 - 1835
  • [3] Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer
    Beyar-Katz, Ofrat
    Dickstein, Yaakov
    Borok, Sara
    Vidal, Liat
    Leibovici, Leonard
    Paul, Mical
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (06):
  • [4] Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients:: An analysis of two case-control studies
    Campos Furtado, Guilherme Henrique
    Mendes, Rodrigo Elisandro
    Campos Pignatari, Antonio Carlos
    Wey, Sergio Barsanti
    Servolo Medeiros, Eduardo Alexandrino
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2006, 34 (07) : 447 - 451
  • [5] Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study
    Cho, Sung-Yeon
    Lee, Dong-Gun
    Choi, Su-Mi
    Kwon, Jae-Cheol
    Kim, Si-Hyun
    Choi, Jae-Ki
    Park, Sun Hee
    Park, Yeon-Joon
    Choi, Jung-Hyun
    Yoo, Jin-Hong
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [6] Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
    Freifeld, Alison G.
    Bow, Eric J.
    Sepkowitz, Kent A.
    Boeckh, Michael J.
    Ito, James I.
    Mullen, Craig A.
    Raad, Issam I.
    Rolston, Kenneth V.
    Young, Jo-Anne H.
    Wingard, John R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 52 (04) : E56 - E93
  • [7] Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients
    Gudiol, C.
    Bodro, M.
    Simonetti, A.
    Tubau, F.
    Gonzalez-Barca, E.
    Cisnal, M.
    Domingo-Domenech, E.
    Jimenez, L.
    Carratala, J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (05) : 474 - 479
  • [8] Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes
    Gudiol, Carlota
    Ayats, Josefina
    Camoez, Mariana
    Angeles Dominguez, M.
    Garcia-Vidal, Carolina
    Bodro, Marta
    Ardanuy, Carmen
    Obed, Mora
    Arnan, Montserrat
    Antonio, Maite
    Carratala, Jordi
    [J]. PLOS ONE, 2013, 8 (09):
  • [9] Updated review of blood culture contamination
    Hall, Keri K.
    Lyman, Jason A.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (04) : 788 - +
  • [10] Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches
    Jubeh, Buthaina
    Breijyeh, Zeinab
    Karaman, Rafik
    [J]. MOLECULES, 2020, 25 (12):